Lv31
210 积分 2022-08-13 加入
[Chinese Expert Consensus on Perioperative Pulmonary Rehabilitation Training
for Lung Cancer]
3小时前
求助中
Brief Report: Osimertinib Plus Capmatinib for Patients with MET-Altered EGFR-Mutant NSCLC following progression on front line therapy
2个月前
已完结
AI-Enabled Lung Cancer Diagnosis and Treatment in China: Challenges, Opportunities, and Future Prospects
3个月前
已完结
[Expert consensus on the management of adverse events of CDK4/6 inhibitors in breast cancer]
5个月前
已完结
Furmonertinib (AST2818) versus gefitinib as first-line therapy for Chinese patients with locally advanced or metastatic EGFR mutation-positive non-small-cell lung cancer (FURLONG): a multicentre, double-blind, randomised phase 3 study
6个月前
已完结
The cancer-immunity cycle: Indication, genotype, and immunotype
7个月前
已完结
Immunotherapy combination approaches: mechanisms, biomarkers and clinical observations
7个月前
已完结
Atezolizumab and Platinum Plus Pemetrexed With or Without Bevacizumab for Metastatic Nonsquamous Non–Small Cell Lung Cancer
8个月前
已完结
Sotorasib for Lung Cancers with KRAS p.G12C Mutation
10个月前
已完结
Adagrasib in Non–Small-Cell Lung Cancer Harboring a KRASG12C Mutation
10个月前
已完结
皖公网安备34019202002308
